Hsu JL, Hung MC (2016) The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer. Cancer Metastasis Rev 35(4):575–588. https://doi.org/10.1007/s10555-016-9649-6
Article CAS PubMed PubMed Central Google Scholar
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–137. https://doi.org/10.1038/35052073
Article CAS PubMed Google Scholar
Iqbal N, Iqbal N (2014) Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications. Mol Biol Int 2014:852748. https://doi.org/10.1155/2014/852748
Article CAS PubMed PubMed Central Google Scholar
Menard S, Casalini P, Campiglio M, Pupa S, Agresti R, Tagliabue E (2001) HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer. Ann Oncol 12(Suppl 1):S15–19. https://doi.org/10.1093/annonc/12.suppl_1.s15
Oh DY, Bang YJ (2020) HER2-targeted therapies - a role beyond breast cancer. Nat Rev Clin Oncol 17(1):33–48. https://doi.org/10.1038/s41571-019-0268-3
Article CAS PubMed Google Scholar
Clifton GT, Peoples AGE (2021) Immunotherapy as a partner for HER2-directed therapies. Expert Rev Anticancer Ther 21(7):739–746. https://doi.org/10.1080/14737140.2021.1894932
Article CAS PubMed Google Scholar
Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28(1):92–98. https://doi.org/10.1200/JCO.2008.19.9844
Article CAS PubMed Google Scholar
Derakhshani A, Rezaei Z, Safarpour H, Sabri M, Mir A, Sanati MA, Vahidian F, Gholamiyan Moghadam A, Aghadoukht A, Hajiasgharzadeh K, Baradaran B (2020) Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol 235(4):3142–3156. https://doi.org/10.1002/jcp.29216
Article CAS PubMed Google Scholar
Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona MS, Prisciandaro M, Fabbroni C, Celio L, Mariani G, Bianchi GV, Capri G, de Braud F (2019) Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: current knowledge, new research directions and therapeutic perspectives. Crit Rev Oncol Hematol 139:53–66. https://doi.org/10.1016/j.critrevonc.2019.05.001
Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E (2022) Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2 + metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis. Ann Oncol 33(3):321–329. https://doi.org/10.1016/j.annonc.2021.12.005
Article CAS PubMed Google Scholar
Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Schneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortes J, Group CS (2015) Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372(8):724–734. https://doi.org/10.1056/NEJMoa1413513
Article CAS PubMed PubMed Central Google Scholar
National Comprehensive Cancer Network Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 2 (2022) (December 20, 2021). https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419. Accessed 06 May 2022
Ulrich L, Okines AFC (2021) Treating advanced unresectable or metastatic HER2-positive breast cancer: a spotlight on tucatinib. Breast Cancer 13:361–381. https://doi.org/10.2147/BCTT.S268451
Article CAS PubMed PubMed Central Google Scholar
National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. United States Department of Health and Human Services, National Institutes of Health, National Cancer Institute (2017) ; https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm. Accessed 13 May 2022
Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228–247. https://doi.org/10.1016/j.ejca.2008.10.026
Article CAS PubMed Google Scholar
Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30(1):52–60. https://doi.org/10.1055/s-0030-1247132
Article CAS PubMed Google Scholar
Sivagnanam K, Rahman ZU, Paul T (2016) Cardiomyopathy associated with targeted therapy for breast cancer. Am J Med Sci 351(2):194–199. https://doi.org/10.1016/j.amjms.2015.11.014
HERCEPTIN® (trastuzumab) intravenous infusion [prescribing information] (2010). Genentech, Inc., South San Francisco, CA
PERJETA® (pertuzumab) injection, for intravenous use [prescribing information]Genentech, Inc., South San Francisco, CA
KADCYLA® (ado- (2019) Trastuzumab emtansine) for injection, for intravenous use [prescribing information]. Genentech, Inc., South San Francisco, CA
ENHERTU® (fam-trastuzumab (2021) deruxtecan-nxki) for injection, for intravenous use [prescribing information]. Daiichi Sankyo, Inc., Basking Ridge, NJ
Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D (2006) Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 23(6):1275–1284. https://doi.org/10.1007/s11095-006-0205-x
Article CAS PubMed Google Scholar
Quartino AL, Li H, Kirschbrown WP, Mangat R, Wada DR, Garg A, Jin JY, Lum B (2019) Population pharmacokinetic and covariate analyses of intravenous trastuzumab (herceptin((R))), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors. Cancer Chemother Pharmacol 83(2):329–340. https://doi.org/10.1007/s00280-018-3728-z
Article CAS PubMed Google Scholar
Carney WP, Bernhardt D, Jasani B (2013) Circulating HER2 extracellular domain: a specific and quantitative biomarker of prognostic value in all breast cancer patients? Biomark Cancer 5:31–39. https://doi.org/10.4137/BIC.S12389
Article CAS PubMed PubMed Central Google Scholar
Petersen ER, Sorensen PD, Jakobsen EH, Madsen JS, Brandslund I (2013) Serum HER-2 predicts response and resistance to trastuzumab treatment in breast cancer. Clin Chem Lab Med 51(7):1483–1492. https://doi.org/10.1515/cclm-2012-0558
Article CAS PubMed Google Scholar
Zhang P, Xiao J, Ruan Y, Zhang Z, Zhang X (2020) Monitoring value of serum HER2 as a predictive biomarker in patients with metastatic breast cancer. Cancer Manag Res 12:4667–4675. https://doi.org/10.2147/CMAR.S254897
Article CAS PubMed PubMed Central Google Scholar
Leyland-Jones B, Smith BR (2011) Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls. Lancet Oncol 12(3):286–295. https://doi.org/10.1016/S1470-2045(10)70297-7
Article CAS PubMed Google Scholar
Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Muller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP (2020) Tucatinib, trastuzumab, and capecitabine for HER2-positive metastatic breast cancer. N Engl J Med 382(7):597–609. https://doi.org/10.1056/NEJMoa1914609
Article CAS PubMed Google Scholar
Wagner AD, Grabsch HI, Mauer M, Marreaud S, Caballero C, Thuss-Patience P, Mueller L, Elme A, Moehler MH, Martens U, Kang YK, Rha SY, Cats A, Tokunaga M, Lordick F (2019) EORTC-1203-GITCG - the “INNOVATION”-trial: effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer Group. BMC Cancer 19(1):494. https://doi.org/10.1186/s12885-019-5675-4
Article CAS PubMed PubMed Central Google Scholar
Hofheinz RD, Haag GM, Ettrich TJ, Borchert K, Kretzschmar A, Teschendorf C, Margareta Siegler G, Ebert MP, Goekkurt E, Welslau M, Mahlberg O, Homann N, Pink D, Bechstein WO, Reichardt P, Gaiser T, Sookthai D, Pauligk C, Goetze TO, Al-Batran SE (2020) Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase II trial of the AIO. J Clin Oncol 38:450
Chung HC, Bang YJ, C SF, Qin SK, Satoh T, Shitara K, Tabernero J, Van Cutsem E, Alsina M, Cao ZA, Lu J, Bhagia P, Shih CS, Janjigian YY (2021) First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncol 17(5):491–501. https://doi.org/10.2217/fon-2020-0737
留言 (0)